DRAPER, Utah, March 05, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its fourth quarter and fiscal year end 2024 financial results following the close of regular stock market trading hours on Tuesday, March 19, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, March 19, 2024, at 4:30 p.m. ET during which management will review the Company’s financial results.
HealthEquity Fourth Quarter and Fiscal Year End 2024 Results Conference Call
| Date: | March 19, 2024 |
| Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
| Dial-In: | 1-833-630-1956 (US and Canada) 1-412-317-1837 (International) |
| Conference ID: | HealthEquity, Inc. call |
| Webcast: | ir.healthequity.com |
A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 15 million benefit accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$96.50 |
| Daily Change: | 0.16 0.17 |
| Daily Volume: | 681,820 |
| Market Cap: | US$8.310B |
September 25, 2025 September 02, 2025 March 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
